Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$172.00 -0.3%	$166.91	$111.09 ▼ $183.00	$10.55B	0.38	499,943 shs	802,076 shs
GMTX Gemini Therapeutics	$52.96 -2.8%	$48.68	$1.16 ▼ $14.10	$2.29B	-0.12	189,291 shs	313,031 shs
ROIV Roivant Sciences	$10.94 -2.9%	$11.14	$8.73 ▼ $13.06	$7.66B	1.15	5.66 million shs	14.00 million shs
SMMT Summit Therapeutics	$21.20 -0.4%	$23.19	$6.78 ▼ $36.91	$15.80B	-1.02	3.65 million shs	2.07 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.35%	-3.96%	+5.28%	+13.05%	+28.38%
GMTX Gemini Therapeutics	-2.83%	+2.48%	+13.45%	+12.32%	+17.51%
ROIV Roivant Sciences	-2.93%	-5.20%	-0.36%	+8.53%	+1.02%
SMMT Summit Therapeutics	-0.38%	+1.34%	+13.61%	+3.62%	+160.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	3.5276 of 5 stars	4.5	3.0	0.0	0.0	2.3	1.7	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	2.0945 of 5 stars	3.5	1.0	0.0	0.0	2.7	2.5	0.0
SMMT Summit Therapeutics	2.6367 of 5 stars	4.4	1.0	0.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	28.29% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
ROIV Roivant Sciences	3.00	Buy	$17.50	59.96% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	63.52% Upside

Current Analyst Ratings Breakdown

Latest GMTX, ROIV, SMMT, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/9/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$201.00 ➝ $216.00
6/3/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$196.00 ➝ $201.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/12/2025	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$393.54M	26.72	N/A	N/A	($1.88) per share	-91.49
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
ROIV Roivant Sciences	$29.05M	256.01	N/A	N/A	$7.45 per share	1.47
SMMT Summit Therapeutics	$700K	22,492.29	N/A	N/A	$0.53 per share	40.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	716.67	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)

Latest GMTX, ROIV, SMMT, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.04	0.71
GMTX Gemini Therapeutics	N/A	71.49	71.49
ROIV Roivant Sciences	N/A	33.47	33.47
SMMT Summit Therapeutics	N/A	10.63	10.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
GMTX Gemini Therapeutics	75.42%
ROIV Roivant Sciences	64.76%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
GMTX Gemini Therapeutics	12.90%
ROIV Roivant Sciences	7.90%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable

GMTX, ROIV, SMMT, and ASND Headlines

Recent News About These Companies

Summit Therapeutics PLC (NASDAQ:SMMT) Receives $35.09 Consensus PT from Brokerages

4 hours ago | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC Wainwright

5 hours ago | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)

July 1 at 8:40 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at UBS Group

July 1 at 8:26 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Rating Increased to Hold at Wall Street Zen

June 30 at 2:51 AM | americanbankingnews.com

Summit Therapeutics PLC (NASDAQ:SMMT) Stock Position Lifted by Sovran Advisors LLC

June 29 at 6:41 AM | marketbeat.com

Lisanti Capital Growth LLC Takes Position in Summit Therapeutics PLC (NASDAQ:SMMT)

June 29 at 6:33 AM | marketbeat.com

Wall Street Zen Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"

June 29 at 3:22 AM | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 29 at 3:21 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 27, 2025 | prnewswire.com

Summit Therapeutics Breaks Above 200-Day Moving Average - Bullish for SMMT - Nasdaq

June 26, 2025 | nasdaq.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 22, 2025 | prnewswire.com

World Equity Group Inc. Sells 14,062 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)

June 22, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 15,331 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)

June 21, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Downgraded to "Sell" Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Shares Sold by Five Pine Wealth Management

June 20, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsÂ On Behalf of Investors of Summit Therapeutics Inc.Â - SMMT

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 17, 2025 | prnewswire.com

Summit Therapeutics SMMT Sees Institutional Growth on Nasdaq Composite

June 17, 2025 | kalkinemedia.comK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, ROIV, SMMT, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$172.00 -0.60 (-0.35%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$172.28 +0.28 (+0.16%)

As of 07/1/2025 04:57 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Gemini Therapeutics NASDAQ:GMTX

$52.96 -1.54 (-2.83%)

As of 06/30/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$10.94 -0.33 (-2.93%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$10.91 -0.03 (-0.27%)

As of 04:11 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Summit Therapeutics NASDAQ:SMMT

$21.20 -0.08 (-0.38%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$21.81 +0.61 (+2.88%)

As of 06:04 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time